<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01104337</url>
  </required_header>
  <id_info>
    <org_study_id>INPAWA2-URT</org_study_id>
    <nct_id>NCT01104337</nct_id>
  </id_info>
  <brief_title>Drug Interaction Between Paracetamol and Warfarin</brief_title>
  <acronym>INPAWA2</acronym>
  <official_title>Dose-dependent Drug-drug Interaction Between Paracetamol and Warfarin in Adults Receiving Long-term Oral Anticoagulants: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Lariboisière</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Lariboisière</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate whether paracetamol, given at therapeutic doses
      (2g/day and 3 g/day), may potentiate the anticoagulant effect of warfarin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Paracetamol is recommended as a first-line analgesic and antipyretic therapy in patients
      receiving short- and long-term oral anticoagulation, especially elderly
      patient.However,Increased INR was previously observed in patients treated with warfarin and
      paracetamol given at the maximum recommended dose (4g/day).

      To date, the mechanism of this interaction has not been determined.A recent in vitro study
      suggested that the toxic metabolite N-acetyl-para-benzoquinoneimine (NAPQI) appeared to
      interfere with vitamin K-dependent γ-carboxylase (VKD-carb) and vitamin K epoxide reductase
      (VKOR) activites12. The question remaining to be dealt with is whether this in vitro
      observation can explain the in vivo paracetamol-warfarin interaction. We aim to evaluate the
      effect of paracetamol at the most widely used doses 2 and 3g/day on INR in stable patients
      treated with warfarin in a double blind randomized placebo-controlled trial and to identify
      the mechanism involved in this interaction in vivo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean maximum increase in INR from baseline to Day 10 (INR (max-D1))</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The mean maximum INR (INRmax)</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to the first variation of INR observed</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 10 - Day 1 differences in factors II, V, VII, AT-III plasma concentrations between groups.</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 10 - Day 1 differences in paracetamol plasma concentration between groups.</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 10 - Day 1 differences in R(-), S(-)warfarin plasma concentrations between groups.</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 10 - Day 1 differences in Gla-type Osteocalcin (Gla-OC) and undercarboxylated Osteocalcin (Glu-OC)plasma concentrations between groups.</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relation between age and the mean maximum increase in INR from baseline to Day 10 (INR (max-D1)</measure>
    <time_frame>10 days</time_frame>
    <description>Relation between age and INR (max-D1)is measured using regression analysis.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Deep Venous Thrombosis</condition>
  <condition>Pulmonary Embolism</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <condition>Antiphospholipid Syndrome</condition>
  <arm_group>
    <arm_group_label>Paracetamol 2g/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18 patients on stable warfarin therapy received a 10-day regimen of paracetamol 2g/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paracetamol 3g/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18 patients on stable warfarin therapy received a 10-day regimen of paracetamol 3g/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>9 patients on stable warfarin therapy received a 10-day regimen of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paracetamol</intervention_name>
    <description>Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets twice a day along with two matching placebo tablets once daily</description>
    <arm_group_label>Paracetamol 2g/d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paracetamol</intervention_name>
    <description>Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets three times a day</description>
    <arm_group_label>Paracetamol 3g/d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Treatment consisted of two matching placebo tablets three times a day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients treated with warfarin (target INR 2 to 3) stable anticoagulation at 2 to 9 mg
             for more than 30 days

          -  Aged 18 years or older

          -  Laboratory values (hemoglobin, blood cell counts, albumin, blood ionogram,
             complementary hemostasis parameters and aspartate, alanine transaminases (AST and
             ALT))remained within normal limits

        Exclusion Criteria:

          -  Any treatment change within 7 days before enrollment

          -  Any paracetamol intake within the last 14 days

          -  Drug allergy Concomitant drug ( 5-fluorouracile, acetylsalicylic acid, non steroidal
             anti-inflammatory drugs, chloramphenicol, diflunisal, miconazole)

          -  St John's wort treatment

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephane Mouly, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Therapeutic Research Unit, Department of Internal Medicine, Hospital Lariboisière, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guy Simoneau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Therapeutic Research Unit, Department of Internal Medicine, Hospital Lariboisière, Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Therapeutic Research Unit, Department of Internal Medicine, Hospital Lariboière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2010</study_first_submitted>
  <study_first_submitted_qc>April 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2010</study_first_posted>
  <last_update_submitted>April 13, 2010</last_update_submitted>
  <last_update_submitted_qc>April 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Pr Stephane Mouly</name_title>
    <organization>Therapeutic Research Unit, Department of Internal Medicine, Hospital Lariboisière, Paris,France</organization>
  </responsible_party>
  <keyword>paracetamol</keyword>
  <keyword>warfarin</keyword>
  <keyword>drug interaction</keyword>
  <keyword>pathogenic mechanism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

